A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Elizabeth R. Allen, Stefanie A. Krumm, Jayna Raghwani, Steinar Halldorsson, Angela Elliott, Victoria A. Graham, Elina Koudriakova, Karl Harlos, Daniel Wright, George M. Warimwe, Benjamin Brennan, Juha T. Huiskonen, Stuart D. Dowall, Richard M. Elliott, Oliver G. Pybus, Dennis R. Burton, Roger Hewson, Katie J. Doores*, Thomas A. Bowden

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)
86 Downloads (Pure)


Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.

Original languageEnglish
Pages (from-to)3750-3758.e4
JournalCell Reports
Issue number13
Early online date26 Dec 2018
Publication statusPublished - 26 Dec 2018


  • antibody
  • antiviral
  • bunyavirus
  • immune response
  • neutralization
  • phlebovirus
  • Rift Valley fever virus
  • structure
  • vaccine
  • virus-host interactions

Cite this